These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34649978)

  • 1. Randomised trial of the P2X
    Niimi A; Saito J; Kamei T; Shinkai M; Ishihara H; Machida M; Miyazaki S
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34649978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough.
    McGarvey L; Smith JA; Morice A; Birring SS; Chung KF; Dicpinigaitis PV; Niimi A; Benninger MS; Sher M; Matsunaga Y; Miyazaki S; Machida M; Ishihara H; Mahmood A; Gomez JC
    Lung; 2023 Feb; 201(1):25-35. PubMed ID: 36512069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Druggable site near the upper vestibule determines the high affinity and P2X3 homotrimer selectivity of sivopixant/S-600918 and its analogue DDTPA.
    Wang DP; Zhang M; Li M; Yang XN; Li C; Cao P; Zhu MX; Tian Y; Yu Y; Lei YT
    Br J Pharmacol; 2024 Apr; 181(8):1203-1220. PubMed ID: 37921202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of gefapixant, a P2X
    McGarvey LP; Birring SS; Morice AH; Dicpinigaitis PV; Pavord ID; Schelfhout J; Nguyen AM; Li Q; Tzontcheva A; Iskold B; Green SA; Rosa C; Muccino DR; Smith JA;
    Lancet; 2022 Mar; 399(10328):909-923. PubMed ID: 35248186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
    Abdulqawi R; Dockry R; Holt K; Layton G; McCarthy BG; Ford AP; Smith JA
    Lancet; 2015 Mar; 385(9974):1198-205. PubMed ID: 25467586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
    Morice A; Smith JA; McGarvey L; Birring SS; Parker SM; Turner A; Hummel T; Gashaw I; Fels L; Klein S; Francke K; Friedrich C
    Eur Respir J; 2021 Nov; 58(5):. PubMed ID: 33986030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
    Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A
    Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
    Garceau D; Chauret N
    Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: A systematic review and meta-analysis of 11 randomized controlled trials.
    Ramadan A; El-Samahy M; Elrosasy A; Al-Tawil M; Abdelaziz A; Soliman MA; Abouzid M
    Pulm Pharmacol Ther; 2023 Dec; 83():102252. PubMed ID: 37678663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial.
    Friedrich C; Francke K; Birring SS; van den Berg JWK; Marsden PA; McGarvey L; Turner AM; Wielders P; Gashaw I; Klein S; Morice AH
    Respir Res; 2023 Apr; 24(1):109. PubMed ID: 37041539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
    McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS
    Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefapixant in two randomised dose-escalation studies in chronic cough.
    Smith JA; Kitt MM; Butera P; Smith SA; Li Y; Xu ZJ; Holt K; Sen S; Sher MR; Ford AP
    Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31949115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough: Dose-Response Model-Based Network Meta-Analysis.
    Yamamoto S; Horita N; Hara J; Sasamoto M; Kanemitsu Y; Hara Y; Obase Y; Kaneko T; Niimi A; Mukae H
    Chest; 2024 Nov; 166(5):1124-1140. PubMed ID: 38857780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men.
    Friedrich C; Singh D; Francke K; Klein S; Hetzel T; Zolk O; Gashaw I; Scheerans C; Morice A
    Br J Clin Pharmacol; 2024 Aug; 90(8):2004-2018. PubMed ID: 38775025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefapixant: First Approval.
    Markham A
    Drugs; 2022 Apr; 82(6):691-695. PubMed ID: 35347635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
    Kum E; Patel M; Diab N; Wahab M; Zeraatkar D; Chu DK; O'Byrne PM; Guyatt GH; Satia I
    JAMA; 2023 Oct; 330(14):1359-1369. PubMed ID: 37694849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
    Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D
    Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
    Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.